Tripartite Motif (TRIM) is a part of a family of proteins that induce interferons and are involved in pathogen recognition during infection as an important component of resistance against some pathogens.
Although human TRIM56, as part of the E3 ligase family, has not been found to impact propagation of all positive strand RNA viruses, it does possess antiviral activity against two classical flaviviruses, Dengue fever and yellow fever as well as the human coronavirus, HCov-OC43, a common coronavirus causing mild common colds. TRIM56 is increasingly recognised as an active participant in antiviral innate immunity but is not indiscriminate in its action on all viruses but TRIM56 has been reported to inhibit flavi-virus RNA replication and also acts at the stage of coronavirus packaging/release, after single stranded helicase RNA viruses replicate the RNA genome, undergo ribosome biogenesis, transcribe mRNA, and undergo splicing, maturation, RNA export/degradation and RNA translation.
Are there any human clinical trials taking place, following the recently discovered antiviral properties of TRIM56 in animal models?